Gemini Therapeutics, Inc. GMTX Stock
1.35 USD
{{ price }}
0.000000%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
58.49M USD
LOW - HIGH [24H]
0.0000
-
0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Gemini Therapeutics, Inc. Price Chart
Gemini Therapeutics, Inc. GMTX Financial and Trading Overview
| Gemini Therapeutics, Inc. stock price | 1.35 USD |
| Previous Close | 1.35 USD |
| Open | 1.36 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1800 |
| Day's Range | 1.35 - 1.41 USD |
| 52 Week Range | 1.35 - 21.8 USD |
| Volume | 60.42K USD |
| Avg. Volume | 24.55K USD |
| Market Cap | 58.49M USD |
| Beta (5Y Monthly) | -0.299392 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.5 USD |
GMTX Valuation Measures
| Enterprise Value | -17959760 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.88235295 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.41322315 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.325 |
Trading Information
Gemini Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | -0.299392 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 21.8 USD |
| 52 Week Low | 1.35 USD |
| 50-Day Moving Average | 16.72 USD |
| 200-Day Moving Average | 15.86 USD |
GMTX Share Statistics
| Avg. Volume (3 month) | 24.55K USD |
| Avg. Daily Volume (10-Days) | 77.58K USD |
| Shares Outstanding | 43.33M |
| Float | 12.05M |
| Short Ratio | 14.22 |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 86.89% |
| Shares Short | 1.42M |
| Short % of Float | 6.32% |
| Short % of Shares Outstanding | 3.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2021 |
| Most Recent Quarter (mrq) | June 30, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.27% |
| Return on Equity (ttm) | -44.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -55283500 USD |
| Net Income Avi to Common (ttm) | -58695000 USD |
| Diluted EPS (ttm) | -2.85 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 108.66M USD |
| Total Cash Per Share (mrq) | 2.51 USD |
| Total Debt (mrq) | 2.91M USD |
| Total Debt/Equity (mrq) | 2.73 USD |
| Current Ratio (mrq) | 17.578 |
| Book Value Per Share (mrq) | 3.267 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -54601000 USD |
| Levered Free Cash Flow (ttm) | -30799750 USD |
Profile of Gemini Therapeutics, Inc.
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 300 One Kendall Square |
| ZIP | 02139 |
| Phone | 617 401 4400 |
| Website | https://www.geminitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 24 |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Gemini Therapeutics, Inc. Stock
What is a current GMTX stock price?
Gemini Therapeutics, Inc. GMTX stock price today per share is 1.35 USD.
How to purchase Gemini Therapeutics, Inc. stock?
You can buy GMTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gemini Therapeutics, Inc.?
The stock symbol or ticker of Gemini Therapeutics, Inc. is GMTX.
Which industry does the Gemini Therapeutics, Inc. company belong to?
The Gemini Therapeutics, Inc. industry is Biotechnology.
How many shares does Gemini Therapeutics, Inc. have in circulation?
The max supply of Gemini Therapeutics, Inc. shares is 43.33M.
What is Gemini Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Gemini Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Gemini Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Gemini Therapeutics, Inc. EPS is 0 USD over the trailing 12 months.
Which sector does the Gemini Therapeutics, Inc. company belong to?
The Gemini Therapeutics, Inc. sector is Healthcare.
Gemini Therapeutics, Inc. GMTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}